FOXP3 and rheumatoid arthritis: Impaired Treg suppressive activity in patients with active RA may be improved by MTX treatment through the demethylation of FOXP3, leading to an increased expression of Foxp3 and cytotoxic T-lymphocyte–associated antigen 4 (13).